Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
Indiana University · NCT07288827
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 6+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- May 4, 2023
- Record last updated
- December 17, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to look at children with PCD and see if they have another condition called "bronchial hyperresponsiveness".
Being studied: Lung Function Testing; Phlebotomy; Allergy skin prick testing; Methacholine Challenge
Conditions: Primary Ciliary Dyskinesia; Healthy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Confirmed diagnosis of PCD per standard diagnostic criteria4 and positive genetics
- Age greater than or equal to 6 years (no upper age limit)
- Any gender or race
- Able to perform pulmonary function testing (historical documentation of reversibility will be accepted)
Exclusion Criteria
- history of current pneumothorax
- inability to perform pulmonary function testing
Recruiting US locations
Riley Hospital for Children
Indianapolis, IN 46202
Site contact: Fanmuyi Yang, PhD
Study contacts (from the official record)
- Fanmuyi Yang, PhD · 317-274-8895 · fy5@iu.edu
- Lisa Bendy · 317-278-7152 · lbendy@iu.edu
Similar studies in Indiana
All healthy volunteers studies in Indiana →- RecruitingHealthy volunteersEarly Phase 1Overnight stay mentioned
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
Indiana University
- Location
- Indianapolis, IN
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Plainfield, IN + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Indianapolis, IN + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1/Phase 2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio, Inc
- Location
- Indianapolis, IN + 5 other US sites
- Eligibility basics
- Ages 18+